FLT3 and acute myeloid leukemia: Randomized phase III RATIFY study led to approval of 7 + 3 + midostaurin as front line for young fit patients [51], and randomized phase III ADMIRAL study with single-agent gilteritinib established the approval of gilteritinib for the treatment of R/R FLT3-mutated AML [52].